The increasing use of GLP-1 drugs has led to higher healthcare premiums due to rising pharmacy costs and overall health plan expenses for insurance carriers and employers.
Rising Costs for Healthcare Carriers and Employers
GLP-1 medications, such as semaglutide and tirzepatide, have become essential treatments for Type 2 diabetes and obesity. However, their high costs significantly impact private healthcare insurer and employer-sponsored health plans which are often wholly or partially self-funded. For instance, the average annual cost for adult plan members with Type 2 diabetes who take GLP-1 drugs is approximately $21,758, compared to $13,961 for those who do not use these medications. This results in nearly $7,800 more per member, per year.
Impact on Premiums
As the demand for GLP-1 medications has surged, healthcare insurers and employers have faced escalating pharmacy costs, which in turn have contributed to higher healthcare premiums. Reports indicate that GLP-1 medications now account for over 10% of annual prescription claims within many private insurer and employer-sponsored health plans, up from 6.9% in 2023. The per-member-per-month costs associated with GLP-1 prescriptions have also increased dramatically, from $1.43 in 2019 to $24.59 in 2024, reflecting a staggering 77% annual growth rate.
Private Insurer and Employer Strategies
In response to these rising costs, many insurers and employers are exploring various strategies to manage the financial impact of GLP-1 drugs. This includes increasing premiums, shifting more healthcare costs to employees, implementing prior authorization requirements, and evaluating alternative pharmacy benefit manager arrangements. Additionally, some employers are imposing stricter clinical requirements for coverage, such as BMI thresholds or participation in wellness programs
Conclusion
The growing utilization of GLP-1 drugs is reshaping healthcare costs and premiums, prompting private insurers and employers to balance the immediate financial burden with potential long-term health benefits. As these medications continue to gain popularity, their impact on healthcare premiums will likely remain a significant concern for both private insurers, employers, and employees.
